Search tips
Search criteria 


Logo of jpnSubmit a ManuscriptEmail AlertsAbout JPNJournal of Psychiatry and Neuroscience
J Psychiatry Neurosci. 1999 March; 24(2): 141–146.
PMCID: PMC1188995

T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability.


Although genes play a major role in the etiology of schizophrenia, no major genes involved in this disease have been identified. However, several genes with small effect have been reported, though inconsistently, to increase the risk for schizophrenia. Recently, the 5HT2A 2 allele (T102C polymorphism) was reported to be over-represented in patients with schizophrenia. Other reports have found an excess of allele 2(C) only in schizophrenic patients who are resistant to clozapine, not in those who respond to clozapine. In this study, the 5HT2A receptor allele 2 frequencies were compared between 2 groups of patients with schizophrenia (39 responders and 63 nonresponders) based on long-term outcome and response to typical neuroleptics. A control group of 90 healthy volunteers screened for mental disorders was also included. Genotype 2/2 tended to be more frequent in patients with schizophrenia with poor long-term outcome and poor response to typical neuroleptics (Bonferroni corrected p = 0.09). This difference was significant in men (Bonferroni corrected p = 0.054) but not in women. In addition, the age at first contact with psychiatric care was significantly younger in the patients with schizophrenia with genotype 2/2 than in patients with genotype 1/1. These result suggest that the 5HT2A-receptor gene may play a role in a subset of schizophrenia characterized by poor long-term outcome and poor response to neuroleptics.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Karayiorgou M, Gogos JA. Dissecting the genetic complexity of schizophrenia. Mol Psychiatry. 1997 May;2(3):211–223. [PubMed]
  • Gershon ES, Martinez M, Goldin L, Gelernter J, Silver J. Detection of marker associations with a dominant disease gene in genetically complex and heterogeneous diseases. Am J Hum Genet. 1989 Oct;45(4):578–585. [PubMed]
  • Inayama Y, Yoneda H, Sakai T, Ishida T, Nonomura Y, Kono Y, Takahata R, Koh J, Sakai J, Takai A, et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet. 1996 Feb 16;67(1):103–105. [PubMed]
  • Williams J, Spurlock G, McGuffin P, Mallet J, Nöthen MM, Gill M, Aschauer H, Nylander PO, Macciardi F, Owen MJ. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet. 1996 May 11;347(9011):1294–1296. [PubMed]
  • Spurlock G, Heils A, Holmans P, Williams J, D'Souza UM, Cardno A, Murphy KC, Jones L, Buckland PR, McGuffin P, et al. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry. 1998 Jan;3(1):42–49. [PubMed]
  • Malhotra AK, Goldman D, Ozaki N, Breier A, Buchanan R, Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry. 1996 Aug;153(8):1092–1094. [PubMed]
  • Arranz MJ, Lin MW, Powell J, Kerwin R, Collier D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 1996 Jun 29;347(9018):1831–1832. [PubMed]
  • Nimgaonkar VL, Zhang XR, Brar JS, DeLeo M, Ganguli R. 5-HT2 receptor gene locus: association with schizophrenia or treatment response not detected. Psychiatr Genet. 1996 Spring;6(1):23–27. [PubMed]
  • Williams J, McGuffin P, Nöthen M, Owen MJ. Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. Lancet. 1997 Apr 26;349(9060):1221–1221. [PubMed]
  • Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet. 1995 Jul 29;346(8970):281–282. [PubMed]
  • Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J, Kirov G, Collier DA, Kerwin RW. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry. 1998 Jan;3(1):61–66. [PubMed]
  • Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA, Kerwin RW. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res. 1998 Jul 27;32(2):93–99. [PubMed]
  • Masellis M, Paterson AD, Badri F, Lieberman JA, Meltzer HY, Cavazzoni P, Kennedy JL. Genetic variation of 5-HT2A receptor and response to clozapine. Lancet. 1995 Oct 21;346(8982):1108–1108. [PubMed]
  • Ichinose H, Nagatsu T. Molecular genetics of hereditary dystonia--mutations in the GTP cyclohydrolase I gene. Brain Res Bull. 1997;43(1):35–38. [PubMed]
  • Blacker D, Tanzi RE. The genetics of Alzheimer disease: current status and future prospects. Arch Neurol. 1998 Mar;55(3):294–296. [PubMed]
  • Breitner JC, Jarvik GP, Plassman BL, Saunders AM, Welsh KA. Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population-based study of men aged 62-73 years. Alzheimer Dis Assoc Disord. 1998 Mar;12(1):40–44. [PubMed]
  • Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, Kulhanek F, Liberman RP, Malm U, Midha KK. Defining treatment refractoriness in schizophrenia. Schizophr Bull. 1990;16(4):551–561. [PubMed]
  • Kolakowska T, Williams AO, Ardern M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry. 1985 Mar;146:229–239. [PubMed]
  • Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, Chakos M, Koreen A, Jody D, Kane J, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry. 1995 May;152(5):698–703. [PubMed]
  • Lindström EM, Ohlund LS, Lindström LH, Ohman A. Symptomatology and electrodermal activity as predictors of neuroleptic response in young male schizophrenic inpatients. Psychiatry Res. 1992 May;42(2):145–158. [PubMed]
  • McDermott BE, Sautter FJ, Garver DL. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response. Psychiatry Res. 1991 Apr;37(1):97–103. [PubMed]
  • Mazure CM, Nelson JC, Jatlow PI, Bowers MB. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry. 1991 Sep 1;30(5):475–482. [PubMed]
  • Bartlett EJ, Brodie JD, Simkowitz P, Schlösser R, Dewey SL, Lindenmayer JP, Rusinek H, Wolkin A, Cancro R, Schiffer W. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am J Psychiatry. 1998 Mar;155(3):337–343. [PubMed]
  • Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry. 1991 Mar;48(3):239–246. [PubMed]
  • Miller RS, Peterson GM, McLean S, Westhead TT, Gillies P. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate. J Clin Pharm Ther. 1995 Apr;20(2):55–62. [PubMed]
  • Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry. 1989 Jul;146(7):905–908. [PubMed]
  • Meltzer HY, Lee M, Cola P. The evolution of treatment resistance: biologic implications. J Clin Psychopharmacol. 1998 Apr;18(2 Suppl 1):5S–11S. [PubMed]
  • Szymanski S, Lieberman J, Pollack S, Kane JM, Safferman A, Munne R, Umbricht D, Woerner M, Masiar S, Kronig M. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry. 1996 Feb 15;39(4):249–254. [PubMed]
  • Nurnberger JI, Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry. 1994 Nov;51(11):849–864. [PubMed]
  • Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull. 1988;24(1):112–117. [PubMed]
  • Warren JT, Jr, Peacock ML, Rodriguez LC, Fink JK. An MspI polymorphism in the hyman serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis. Hum Mol Genet. 1993 Mar;2(3):338–338. [PubMed]
  • Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, Cola P, Howard A, Badri F, Nöthen MM, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 1998 Aug;19(2):123–132. [PubMed]
  • Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976 Jun;33(6):766–771. [PubMed]
  • Ozaki N, Manji H, Lubierman V, Lu SJ, Lappalainen J, Rosenthal NE, Goldman D. A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem. 1997 May;68(5):2186–2193. [PubMed]

Articles from Journal of Psychiatry & Neuroscience : JPN are provided here courtesy of Canadian Medical Association